Opinion
Video
Author(s):
Experts on non–muscle invasive bladder cancer discuss promising developments in the overall treatment landscape, highlighting potentially practice-changing clinical research.
Disitamab vedotin plus toripalimab extends PFS, OS in HER2-positive la/mUC
Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care
Physical function and frailty measures offer distinct insights in patients with bladder cancer
Dr. Lutz on sexual dysfunction, performance anxiety, and Peyronie's disease
FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
FDA updates in urology: April 2025